- Investing.com
BioVersys AG, a clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria. It develops BV100 that is in Phase 3 clinical trial for carbapenem resistant Acinetobacter baumannii lung and blood stream infections; and in Phase 1 trial in patients with hepatic impairment and a bronchoalveolar lavage (BAL). The company is also developing Alpibectir that is in Phase 2a clinical trial for the treatment of pulmonary tuberculosis; BV200 to treat patients with Atopic dermatitis Staphylococcus aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop novel ansamycin leads from BV500 program into clinical candidates. The company was founded in 2008 and is based in Basel, Switzerland.
Metrics to compare | BIOV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBIOVPeersSector | |
---|---|---|---|---|
P/E Ratio | −9.3x | 7.6x | −0.5x | |
PEG Ratio | −1.16 | −0.01 | 0.00 | |
Price/Book | - | 1.8x | 2.6x | |
Price / LTM Sales | 144.0x | 2.3x | 3.3x | |
Upside (Analyst Target) | 100.0% | 38.5% | 43.5% | |
Fair Value Upside | Unlock | 20.4% | 6.9% | Unlock |